A major shift is underway in how traumatic brain injuries are diagnosed, documented, and litigated. In February 2026, pharmaceutical giant Roche launched a landmark Phase II/III clinical trial — registered as NCT07455136 — to advance blood-based diagnostic testing for traumatic brain injury using two critical protein biomarkers: GFAP (glial fibrillary acidic protein) and UCH-L1 (ubiquitin carboxy-terminal hydrolase L1). Updated in August 2026, the trial now expects 2,000 study participants with a revised completion date of November 2028. This trial is accelerating what many brain injury attorneys already know: blood biomarkers TBI diagnosis settlement evidence is no longer a future concept — it is the present standard reshaping personal injury claims across the country in 2026.
Roche’s Phase II/III Trial and the Science Behind GFAP and UCH-L1
Roche’s clinical trial NCT07455136, which began on February 9, 2026, and received a significant update in August 2026 — expanding its target enrollment to 2,000 participants and pushing its completion date to November 2028 — represents one of the most significant investments in objective TBI diagnostics in recent history. This momentum builds on a critical regulatory milestone: the FDA has now granted approval for both GFAP and UCH-L1 biomarkers for clinical use in mild and moderate TBI, cementing their role as legitimate, court-ready diagnostic tools. Abbott’s i-STAT TBI Plasma test, which measures both markers directly from a blood draw, has also been registered in Europe, signaling global adoption. Roche’s Phase II/III trial builds on this foundation, aiming to further validate, standardize, and expand clinical use of these biomarkers across diverse patient populations and injury severities.
GFAP is a structural protein found in astrocytes — the star-shaped glial cells of the brain. When the brain sustains trauma, astrocytes release GFAP into the bloodstream. Critically, GFAP is largely unaffected by extracranial (non-brain) trauma, which means elevated GFAP levels in blood are a targeted signal of brain-specific injury — not a byproduct of general bodily harm. This distinction is enormously important in litigation, where defense attorneys often argue that physical injuries outside the skull could explain a plaintiff’s symptoms.
UCH-L1 is a neuron-specific enzyme involved in protein degradation. Because it is expressed almost exclusively in neurons, elevated UCH-L1 in the bloodstream following a traumatic event provides direct, measurable evidence of neuronal damage. Together, GFAP and UCH-L1 give clinicians — and now, courts — two independent, scientifically validated, FDA-approved markers of brain cell injury. For anyone pursuing a brain injury claim in 2026, blood biomarkers TBI diagnosis settlement evidence built on GFAP and UCH-L1 results may become the cornerstone of a compelling damages case. To understand how this evidence may factor into your overall claim value, explore our personal injury settlement calculator.
Blood Tests vs. CT Scans: What the Research Shows in 2026
For decades, CT imaging has been the front-line diagnostic tool for emergency TBI assessment. Yet CT scans carry well-documented limitations: they expose patients to ionizing radiation, they are costly, and — most critically for mild TBI cases — they frequently return normal results even when a genuine brain injury is present. This is the diagnostic gap that has allowed insurance carriers to dismiss thousands of legitimate TBI claims as “subjective” or “unverifiable.”
The research emerging in 2026 makes the case for biomarker testing more powerfully than ever. A July 2026 multi-center regulatory trial published in The Lancet Regional Health – Americas evaluated a whole-blood point-of-care GFAP/UCH-L1 test across 20 trauma centers, demonstrating high sensitivity for detecting CT-positive intracranial injury. Equally striking are real-world implementation data from a European emergency department study published in August 2026, which found that 42% of mild TBI patients were able to avoid CT scanning entirely based on biomarker results alone, with an additional 12% ruled out through clinical assessment. Combined, that means more than half of mild TBI patients in that study received a clinically sound ruling without radiation exposure — while simultaneously generating the kind of objective diagnostic documentation that supports a personal injury claim. A 2024 systematic review published on PubMed (NCBI) had already confirmed that blood-based biomarker testing can significantly reduce unnecessary CT scans in mild TBI management, and the 2026 data now validates that finding at scale across real emergency settings.
For brain injury victims and their attorneys, the implications are profound. A plaintiff who presents with post-concussive symptoms but a normal CT scan has historically faced an uphill battle against insurers who characterize their injuries as unproven. Biomarker testing fills that evidentiary void with hard, laboratory-confirmed data — data that is now FDA-approved, peer-reviewed, and increasingly accepted in both clinical and legal settings.
How Blood Biomarker Evidence Strengthens TBI Settlement Cases
The introduction of FDA-approved GFAP and UCH-L1 testing into mainstream clinical practice is fundamentally changing the settlement landscape for TBI victims in 2026. Historically, mild and moderate TBI cases were among the most difficult to litigate precisely because the injuries were difficult to prove with traditional imaging. A plaintiff complaining of headaches, cognitive fog, mood disturbances, and sleep disruption after a car accident — but with a normal CT scan — was vulnerable to defense arguments that the symptoms were exaggerated, pre-existing, or psychosomatic.
Blood biomarker results change that calculus entirely. When a plaintiff’s GFAP or UCH-L1 levels are objectively elevated in the hours following a traumatic event, that data provides an independent, biological confirmation of brain injury that is extraordinarily difficult for defense counsel to attack. The biomarkers are not self-reported. They are not subject to symptom magnification. They are measurable proteins released by damaged brain cells — and their presence in the bloodstream tells a story that juries and adjusters alike can understand.
In terms of settlement values, 2026 data reflects the seriousness with which these claims are now being treated. According to July 2026 figures from Novian & Novian Law, TBI settlements currently range from approximately $20,000 for mild cases to well over $10 million for catastrophic injuries, with some exceptional cases exceeding $26 million. While settlement value always depends on the specific facts, jurisdiction, and quality of legal representation, the availability of objective biomarker evidence consistently pushes case valuations higher — particularly in mild TBI cases where establishing injury causation was previously the central battleground.
Attorneys handling TBI claims in 2026 should be actively incorporating biomarker evidence into their case-building strategy from the earliest stages. This means advising clients to seek biomarker testing promptly after injury, preserving laboratory results in the medical record, and retaining experts who can explain the clinical significance of GFAP and UCH-L1 elevations to a lay jury. For a preliminary estimate of what a biomarker-supported TBI claim may be worth, visit our personal injury settlement calculator.
Insurance Defense Tactics and Why Biomarkers Close the Door
Insurance defense attorneys have long relied on a predictable playbook when contesting TBI claims: challenge the plaintiff’s credibility, emphasize the absence of objective findings on CT or MRI, retain neuropsychologists to argue that reported symptoms are inconsistent or exaggerated, and suggest that pre-existing conditions account for the plaintiff’s complaints. In many mild TBI cases, this strategy has been devastatingly effective — not because the injuries were not real, but because the diagnostic tools available to plaintiffs simply could not produce the kind of hard, biological evidence that silences a skilled defense team.
FDA-approved GFAP and UCH-L1 biomarker testing dismantles that playbook. When a plaintiff’s bloodwork — drawn in an emergency department within hours of the accident — shows elevated levels of brain-specific proteins, the defense faces a fundamentally different challenge. They cannot argue that the plaintiff fabricated elevated GFAP levels. They cannot claim that UCH-L1 elevation is the result of symptom magnification. The biological data exists in the medical record, was collected under clinical protocols, and reflects an objective physiological event: the release of brain cell proteins into the bloodstream following trauma.
Defense teams in 2026 have attempted to counter biomarker evidence by challenging the novelty of the testing, questioning chain-of-custody protocols, or arguing that elevated levels fall within borderline ranges. However, with the FDA’s formal approval of GFAP and UCH-L1 for clinical use in mild and moderate TBI, and with high-sensitivity multi-center validation data now published in leading peer-reviewed journals including The Lancet Regional Health – Americas, these arguments are increasingly difficult to sustain before informed judges and juries.
The practical result is that insurers are becoming more willing to negotiate meaningful settlements in mild TBI cases that are supported by biomarker evidence — rather than risk a jury verdict that reflects the full weight of an objectively documented brain injury.
What Brain Injury Victims and Their Attorneys Should Do in 2026
If you or a client has sustained a head injury in an accident in 2026, the single most important early step — beyond immediate medical care — is to request GFAP and UCH-L1 blood biomarker testing as soon as possible. These markers are most reliably elevated within the first 12 hours following injury, though GFAP in particular has been shown to remain detectable for longer periods. Many hospital emergency departments and urgent care centers now offer this testing given its FDA-approved status, but patients and families must be proactive in asking for it, as it is not yet universally offered as a default protocol at every facility.
For attorneys, the 2026 landscape demands an updated intake and case-development protocol that treats biomarker evidence as a priority. This includes:
- Immediately advising injured clients to seek emergency evaluation and specifically request GFAP/UCH-L1 testing if not already performed
- Obtaining and preserving all laboratory records documenting biomarker levels, collection times, and reference ranges
- Retaining neurological experts familiar with the clinical literature, including the July 2026 Lancet Regional Health – Americas multi-center trial and the European emergency department implementation data, who can contextualize the findings for a jury
- Using biomarker results to anchor damages arguments, particularly in mild TBI cases where CT and MRI findings may be normal
- Monitoring the progress of Roche’s NCT07455136 trial — now targeting 2,000 participants with a November 2028 completion date — for additional peer-reviewed validation data that may strengthen future cases
Brain injury victims should also be aware that the window for collecting meaningful biomarker evidence is narrow. Delays in seeking medical care — even delays of a day or two — can result in biomarker levels returning to baseline, potentially eliminating this powerful form of documentation. Prompt evaluation is both a medical and a legal imperative.
For a preliminary assessment of what your TBI claim may be worth in 2026, use our personal injury settlement calculator as a starting point before consulting with a qualified brain injury attorney in your jurisdiction.
Frequently Asked Questions About Blood Biomarkers and TBI Settlement Evidence
What are GFAP and UCH-L1, and why do they matter for my TBI claim?
GFAP (glial fibrillary acidic protein) and UCH-L1 (ubiquitin carboxy-terminal hydrolase L1) are proteins released into the bloodstream when brain cells are damaged. GFAP originates from astrocytes — supporting cells of the brain — while UCH-L1 comes from neurons. Both are highly brain-specific, meaning their elevation in blood following a traumatic event is a targeted indicator of brain injury rather than general bodily trauma. The FDA has formally approved both biomarkers for clinical use in mild and moderate TBI. For your legal claim, elevated GFAP or UCH-L1 results in your medical records provide objective, biological proof of brain injury that is independent of your reported symptoms — making it significantly harder for insurance companies to dismiss your case as subjective or unverifiable.
Can a blood biomarker test detect a mild TBI that a CT scan missed?
Yes — and this is one of the most important developments in TBI diagnostics in 2026. CT scans are well-known to miss mild traumatic brain injuries because they detect structural damage visible to imaging, not the cellular-level injury that characterizes many concussions and mild TBIs. Blood biomarker testing measures the actual biological byproducts of brain cell damage, which can be present even when CT results are completely normal. A July 2026 multi-center regulatory trial published in The Lancet Regional Health – Americas confirmed that whole-blood point-of-care GFAP/UCH-L1 testing demonstrated high sensitivity for detecting intracranial injury across 20 trauma centers. Real-world data from a European emergency department study published in August 2026 further showed that 42% of mild TBI patients avoided CT scanning based on biomarker results, with an additional 12% ruled out through clinical assessment — demonstrating both the clinical utility and the practical reach of this technology.
Will insurance companies accept blood biomarker results as evidence of TBI?
Increasingly, yes — particularly now that GFAP and UCH-L1 have received FDA approval for clinical use in mild and moderate TBI and have been validated across large-scale, multi-center clinical trials published in leading peer-reviewed journals. While individual insurance adjusters and defense attorneys may still attempt to challenge or minimize biomarker evidence, the scientific and regulatory foundation supporting these tests is now robust enough that such challenges are becoming harder to sustain. Insurers are acutely aware that a jury presented with objective laboratory evidence of brain injury is more likely to return a significant verdict — which creates meaningful settlement pressure. TBI settlements in 2026 range from approximately $20,000 for mild cases to over $10 million for catastrophic injuries, with some exceptional cases exceeding $26 million, and biomarker evidence is one of the factors that consistently supports higher valuations.
How soon after a head injury should I get a GFAP/UCH-L1 blood test?
As soon as possible — ideally within the first 12 hours following the injury. Both GFAP and UCH-L1 are most reliably detectable in the acute period immediately following brain trauma. UCH-L1 in particular peaks and clears relatively quickly, while GFAP tends to remain elevated for a longer window. Waiting even 24 to 48 hours may result in levels returning to within normal reference ranges, eliminating the opportunity to capture this critical evidence. If you are treated in an emergency department following a head injury in 2026, proactively request biomarker testing — many facilities now offer it given the FDA-approved status of these markers, but it is not yet universally ordered as a standard protocol. The sooner the test is performed and documented in your medical record, the stronger your evidentiary foundation for any subsequent injury claim.
What is Roche’s NCT07455136 trial, and how does it affect TBI litigation going forward?
NCT07455136 is a Phase II/III clinical trial launched by Roche in February 2026 to further validate and expand the clinical application of GFAP and UCH-L1 biomarker testing for traumatic brain injury. As of August 2026, the trial has been updated to enroll 2,000 study participants, with a revised completion date of November 2028. The trial is designed to generate the kind of large-scale, rigorous clinical evidence that strengthens the scientific consensus around biomarker-based TBI diagnosis across diverse patient populations and injury severities. For TBI litigation, this matters because each wave of peer-reviewed validation data makes it progressively more difficult for defense experts to characterize biomarker testing as experimental or unreliable. As the trial progresses toward its 2028 completion, attorneys handling TBI cases should monitor published interim findings and incorporate the evolving literature into their expert witness strategies and damages arguments.
Robert Callahan is a TBI and Catastrophic Injury Researcher with extensive knowledge of personal injury law and settlement values across the United States. With years of experience analyzing brain injury / tbi claims only cases, Robert helps injury victims understand their legal rights and the potential value of their claims. Robert is not an attorney and the information provided is for educational purposes only.